Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-12-13 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
海创药业股份有限公司董事会战略委员会工作细则（2023年12月修订）
Governance Information Classification · 100% confidence The document is titled as the "Board of Directors Strategic Committee Work Rules" of a company, detailing the structure, responsibilities, meeting procedures, and governance of the board's strategic committee. It is a governance-related internal regulation document rather than a financial report, announcement, or other filing types. There is no indication of financial data, audit information, voting results, or other report types. The content aligns with governance practices and internal board rules, fitting the Governance Information (CGR) category.
2023-12-13 Chinese
关于召开2023年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2023 second extraordinary general meeting of shareholders, detailing the meeting date, voting methods, agenda items, and procedural instructions. It includes an authorization proxy form for shareholders to delegate voting rights. There are no financial statements, earnings data, or audit information. The document is an announcement of a shareholder meeting, not a report or results announcement. It fits the category of a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting.
2023-12-13 Chinese
海创药业股份有限公司董事会审计委员会工作细则（2023年12月修订）
Governance Information Classification · 95% confidence The document is titled "董事会审计委员会工作细则" which translates to "Board Audit Committee Working Rules". It details the structure, responsibilities, decision-making procedures, and meeting rules of the audit committee of the board of directors. It does not contain financial statements, audit opinions, or financial results. Instead, it is a governance document outlining internal rules and procedures related to the audit committee's function within the board. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is about 4986 characters, and it is a full text of the working rules, not an announcement or a brief summary. Therefore, the appropriate classification is CGR with high confidence.
2023-12-13 Chinese
海创药业股份有限公司董事会薪酬与考核委员会工作细则（2023年12月修订）
Governance Information Classification · 100% confidence The document is titled as the "Board of Directors Remuneration and Assessment Committee Work Rules" of a company, detailing the committee's composition, responsibilities, decision-making procedures, and operational rules. It is a governance-related document outlining internal rules and procedures for the board committee on remuneration and assessment. There is no financial data, no report publication, no voting results, no legal proceedings, no capital changes, or other types of filings. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-12-13 Chinese
海创药业股份有限公司董事会议事规则（2023年12月修订）
Governance Information Classification · 100% confidence The document is titled "董事会议事规则" which translates to "Rules of Procedure for the Board of Directors" of the company. It details the composition, powers, meeting procedures, responsibilities, and duties of the board and board secretary. It references relevant laws and regulations governing board operations. There is no financial data, earnings information, or report content. It is a governance document outlining internal rules and governance practices of the company. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, not a brief announcement or a report publication notice.
2023-12-13 Chinese
海创药业股份有限公司董事会提名委员会工作细则（2023年12月修订）
Governance Information Classification · 100% confidence The document is titled as the "Board Nomination Committee Working Rules" of the company, detailing the structure, responsibilities, procedures, and rules of the board nomination committee. It is a governance-related document focused on internal board and management nomination processes, committee composition, and decision-making protocols. There is no financial data, audit information, voting results, or report publication announcement. It is not a report or announcement of financial results or capital changes. The content fits the category of Governance Information, which covers internal rules, board structure, and governance practices.
2023-12-13 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.